 Progress report Stroke Prevention Atrial Fibrillation Study Stroke Prevention Atrial Fibrillation Study SPAF Investigators Engl Med beneficial effect warfarin aspirin placebo primary prevention ischemic stroke systemic embolism patients nonvalvular atrial fibrillation warfarin-eligible patients event rates /yr active antithrombotic therapy warfarin aspirin /yr placebo risk reduction confidence interval beneficial effect aspirin warfarin-ineligible patients basis results study antithrombotic agents Insight apparent aspirin unresponsiveness patients Interpretation preliminary results reshaping study complex continued blinding investigators certain portions data Presented account study inception recent redesign